KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EPS (Basic) (2016 - 2025)

Acadia Pharmaceuticals has reported EPS (Basic) over the past 16 years, most recently at $1.62 for Q4 2025.

  • Quarterly results put EPS (Basic) at $1.62 for Q4 2025, up 86.21% from a year ago — trailing twelve months through Dec 2025 was $2.32 (up 69.34% YoY), and the annual figure for FY2025 was $2.32, up 69.34%.
  • EPS (Basic) for Q4 2025 was $1.62 at Acadia Pharmaceuticals, up from $0.43 in the prior quarter.
  • Over the last five years, EPS (Basic) for ACAD hit a ceiling of $1.62 in Q4 2025 and a floor of -$0.7 in Q1 2022.
  • Median EPS (Basic) over the past 5 years was -$0.04 (2021), compared with a mean of $0.05.
  • Biggest five-year swings in EPS (Basic): crashed 135.29% in 2023 and later soared 1900.0% in 2024.
  • Acadia Pharmaceuticals' EPS (Basic) stood at -$0.27 in 2021, then rose by 3.7% to -$0.26 in 2022, then soared by 207.69% to $0.28 in 2023, then skyrocketed by 210.71% to $0.87 in 2024, then skyrocketed by 86.21% to $1.62 in 2025.
  • The last three reported values for EPS (Basic) were $1.62 (Q4 2025), $0.43 (Q3 2025), and $0.16 (Q2 2025) per Business Quant data.